• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 497648 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1418975303 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1418975303 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Vanda Pharmaceuticals Trading Higher on 1.6x Above-Average Volume (VNDA)

Published on Fri, 05/10/2013 - 13:15
By Peter Chu

Vanda Pharmaceuticals's stock is up 1.6% to $5.14 on heavy trading volume. Today's volume of 371,000 shares tops the average 30-day volume of 232,000 shares. Spikes in volume can validate a breakout or signify a potential turning point.

Vanda Pharmaceuticals share prices have moved between a 52-week high of $5.17 and a 52-week low of $2.92 and are now trading 76% above that low price at $5.14 per share. The 200-day and 50-day moving averages have moved 0.23% higher and 2.04% higher over the past week, respectively.

Potential upside of 65.4% exists for Vanda Pharmaceuticals, based on a current level of $5.14 and analysts' average consensus price target of $8.50. The stock should find initial support at its 50-day moving average (MA) of $4.23 and further support at its 200-day MA of $3.96.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of clinical-stage, small molecule product candidates for central nervous system disorders.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Shares of Western Digital Rise Above Pre...

Shares of Western Digital (NYSE:WDC) traded today at $112.21, breaking its 52-week high ...

WellCare Health Plans: The Winning Strea...

Shares of WellCare Health Plans (NYSE:WCG) traded at a new 52-week high today of $79.34 ...

Shares of Vornado Realty Trust Rise Abov...

Shares of Vornado Realty Trust (NYSE:VNO) traded at a new 52-week high today of $115.96 ...

Watch for Continued Losses in Shares of ...

Shares of UQM Technologies (AMEX:UQM) traded at a new 52-week low today of $0.85. Appr ...

Universal Electronics Looks to Continue ...

Shares of Universal Electronics (NASDAQ:UEIC) traded today at $63.71, breaking its 52-w ...

Shares of United Community Financial Ris...

Shares of United Community Financial (NASDAQ:UCFC) traded today at $5.50, breaking its ...

TriQuint Semiconductor Looks to Continue...

TriQuint Semiconductor (NASDAQ:TQNT) traded at a new 52-week high today of $26.84. Thi ...

Shares of Target Have Risen Above Previo...

Target (NYSE:TGT) traded at a new 52-week high today of $74.87. So far today approxima ...